Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBT Margin (2016 - 2025)

Historic EBT Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 208.39%.

  • Regenxbio's EBT Margin rose 380100.0% to 208.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 110.38%, marking a year-over-year increase of 1731000.0%. This contributed to the annual value of 272.54% for FY2024, which is 196100.0% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's EBT Margin is 208.39%, which was up 380100.0% from 331.91% recorded in Q2 2025.
  • Regenxbio's EBT Margin's 5-year high stood at 77.13% during Q4 2021, with a 5-year trough of 405.63% in Q1 2024.
  • For the 5-year period, Regenxbio's EBT Margin averaged around 239.05%, with its median value being 246.4% (2024).
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -2684800bps in 2022, then surged by 4124300bps in 2025.
  • Over the past 5 years, Regenxbio's EBT Margin (Quarter) stood at 77.13% in 2021, then plummeted by -348bps to 191.35% in 2022, then tumbled by -48bps to 283.8% in 2023, then rose by 15bps to 241.68% in 2024, then rose by 14bps to 208.39% in 2025.
  • Its last three reported values are 208.39% in Q3 2025, 331.91% for Q2 2025, and 6.81% during Q1 2025.